FDA approves Jakafi for polycythemia vera

FDA approved an sNDA under Priority Review for Jakafi ruxolitinib from Incyte Corp. (NASDAQ:INCY) to treat patients

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE